Andere talen BioCryst Pharmaceuticals, Inc.

Aandelen

BCRX

US09058V1035

Biotechnologie & Medisch Onderzoek

Beurs gesloten - Nasdaq Andere beurzen 22:00:00 24-01-2025			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
7,640 ^USD	-1,16%		+2,55%	+1,60%

15/01	BioCryst Pharmaceuticals, Inc. Presents at 43rd Annual J.P. Morgan Healthcare Conference 2025, Jan-14-2025 03:00 PM
10/01	BioCryst Pharmaceuticals voorlopige omzet over Q4 stijgt	MT

Andere talen

BioCryst Pharmaceuticals Preliminary Q4 Revenue Rises	10/01
BioCryst Pharmaceuticals, Inc. Provides Preliminary Unaudited Total Revenue Guidance for the Fourth Quarter and Year 2024 and Year 2025	10/01
BioCryst Announces Preliminary Full Year 2024 ORLADEYO® (berotralstat) Net Revenue of $437 Million (+34 percent y-o-y)	10/01
BioCryst to Present at 43rd Annual J.P. Morgan Healthcare Conference	07/01
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	06/01
KalVista Pharmaceuticals' Sebetralstat Poised to Disrupt Acute HAE Market With Oral Advantage, BofA Says	18/12
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	04/12
BioCryst Pharmaceuticals' Hereditary Angioedema Drug Gets Recommendation From Ireland Regulator	18/11
BioCryst Launches ORLADEYO® (berotralstat) in Ireland	18/11
BioCryst Pharmaceuticals, Inc. Launches ORLADEYO® (berotralstat) in Ireland	18/11
BioCryst to Present at Upcoming Investor Conferences	06/11
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	05/11
BioCryst Pharmaceuticals Q3 Loss Narrows, Revenue Rises; 2024 Sales Guidance Issued	04/11
Earnings Flash (BCRX) BIOCRYST PHARMACEUTICALS Reports Q3 Revenue $117.1M	04/11
Earnings Flash (BCRX) BIOCRYST PHARMACEUTICALS Posts Q3 Loss $-0.07 Per Share	04/11
BioCryst Pharmaceuticals : Reports Third Quarter 2024 Financial Results and Provides Business Update Form 8 K	04/11
BioCryst: Q3 Earnings Snapshot	04/11
BioCryst Reports Third Quarter 2024 Financial Results and Provides Business Update	04/11
BioCryst Pharmaceuticals, Inc. Provides Financial Guidance for the Year 2024, Second Half of 2025 and Full Year of 2026	04/11
BioCryst Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024	04/11
BioCryst Presents New Real-World Evidence Showing High Adherence and Persistence Rates with ORLADEYO® (berotralstat)	24-10-24
BioCryst to Report Third Quarter 2024 Financial Results on November 4	21-10-24
BioCryst to Present New Real-World Evidence Showing Significant Reductions in Medical Visits and Hospitalizations after Starting ORLADEYO	15-10-24
BioCryst Pharmaceuticals' Study of Orladeyo Finds Hospitalization Reduction for Hereditary Angioedema Patients	14-10-24
BioCryst to Present New Real-World Evidence Showing Significant Reductions in Medical Visits and Hospitalizations After Starting ORLADEYO® (berotralstat)	14-10-24

Word de lid om toegang te krijgen tot meer nieuws.

Gratis inschrijven

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen BioCryst Pharmaceuticals, Inc.

Aandelen

BCRX

US09058V1035

Biotechnologie & Medisch Onderzoek

Andere talen

Filters